Loading...
•
Jun 30, 2022
Alnylam Q2 2022 Earnings Report
Alnylam reported strong growth in patient demand and product revenues.
Key Takeaways
Alnylam Pharmaceuticals reported second quarter 2022 financial results, achieving global net product revenues of $214 million, a 33% increase compared to the same period last year. The company also received FDA approval of AMVUTTRA for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and reiterated its 2022 financial guidance.
Achieved Second Quarter 2022 Global Net Product Revenues of $214 Million for ONPATTRO, GIVLAARI, and OXLUMO (33% Growth vs. Same Period Last Year)
Received FDA Approval of AMVUTTRA (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
Expects to Report Topline Results from APOLLO-B Phase 3 Trial of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Within the Next Three Weeks
Reiterated 2022 Financial Guidance, Including Combined Net Product Revenues of $870-$930 Million
Revenue by Segment
Forward Guidance
Full year 2022 financial guidance is reiterated and consists of the following: Combined net product revenues for ONPATTRO, GIVLAARI, OXLUMO and AMVUTTRA $870 million - $930 million ; Net revenues from collaborations and royalties $175 million - $225 million; GAAP R&D and SG&A expenses $1,620 million - $1,700 million; Non-GAAP R&D and SG&A expenses $1,390 million - $1,450 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...